Q-omics provides the consensus-scored TMEM17 profile across patient tissues and cancer cell-line models. TMEM17 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, TMEM17 is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, TMEM17 RNA expression shows 20,862 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight BLCA, KICH, and ACC as cancer lineages where TMEM17 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM17 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM17 survival associations across molecular data types. TMEM17 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM17 RNA expression–survival associations across cancer types. High TMEM17 expression shows unfavorable associations in BLCA, LIHC, ACC, GBM and STAD, but favorable associations in MESO. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for TMEM17 RNA expression.
This table summarizes TMEM17 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 2. The strongest signals are observed in KICH for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for TMEM17. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM17 shows lower tumor expression in KICH and higher tumor expression in HNSC, LIHC, COAD, BLCA and LUSC. The KICH box plot shows higher TMEM17 RNA expression in normal versus tumor tissue (log2 FC = −2.184, t-test p < 0.001).
This table shows molecular features associated with TMEM17 in patient tissues and cancer cell lines. In patient samples, TMEM17 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM17 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BREAST.
